Combination Therapies for Melanoma: A New Standard of Care?
Combination Therapies for Melanoma: A New Standard of Care?
复制标题
DOI：
10.1007/s40257-016-0174-8
复制
发表时间：
2016-04-01
影响因子：
7.3
通讯作者：
Sondak, Vernon K.
中科院分区：
文献类型：
--
作者：
Smalley, Keiran S. M.;Eroglu, Zeynep;Sondak, Vernon K.
最近的数据表明，晚期黑色素瘤患者的靶向和免疫治疗改善了生存率，这在肿瘤学界引起了极大的兴奋，并广泛使用这些药物的联合治疗方案。然而，这些联合疗法在晚期黑色素瘤治疗中的地位仍有待充分确定。在这篇观点文章中，我们批判性地回顾了现有的数据，并概述了这些组合被采纳为未来晚期黑色素瘤患者的标准治疗的理由。
Recent data have demonstrated improved survival with targeted and immune therapies in patients with advanced melanoma, leading to much excitement amongst the oncology community and the widespread use of these drugs in combination regimens. However, the place of these combination therapies in the treatment of advanced melanoma remains to be fully determined. In this perspectives article, we critically review the available data and outline the rationale for these combinations being adopted as the standard of care for patients with advanced melanoma in the future.